Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

Autor: Gordon, K. B, Blauvelt, A., Papp, K. A., Langley, R. G., Luger, T., Ohtsuki, M., Reich, K., Amato, D., Ball, S. G., Braun, D. K., Cameron, G. S., Erickson, J., Konrad, R. J., Muram, T. M., Nickoloff, B. J., Osuntokun, O. O., Secrest, R. J., Zhao, F., Mallbris, L., Leonardi, C. L., Uncover, 1 Study Group: Holly Hake Harris, Matheson, Robert T., Michael, Bukhalo, John H., Tu, Crowley, Jeffrey J., Grande, Kimberly K., Adnan, Nasir, Boni Elizabeth Elewski, James Alan Solomon, Liebhild, Stratmann, Claudia, Buettner, Thomas Peter Dirschka, Margrit Ruth Simon, Jens, Ulrich, Christine, Grigat, Mathias, Augustin, Andrei, Khariouzov, Gerhard, Sattler, Hans Michael Ockenfels, Fredrick Richard Behringer, Hector, Wiltz, Francisco, Flores, Kuettel, Kevin D., Ira Hughes Thorla, Jeffrey Keith Moore, Waterman, Gary L., George Joji Murakawa, Scott Alfred Fretzin, Frankel, Ellen H., Sunil Sharan Dhawan, Lucyna, Leszniewska, Maria, Poznanska, Anna Sobieszek Kundro, Chodorowska, Grazyna M., Katarzyna Turek Urasinska, Romuald, Maleszka, Andrzej, Kaszuba, Lidia, Rajzer, Elizbieta Barbara Szymanska, Lidia, Rudnicka, Neil James Korman, Jamie Debra Weisman, Truett, Artis P., Jeffry, Jacqmein, Steven Robert Cohen, Heller, Gary L., Jenkin, Peter J., Abe, Marcadis, George Sorin Tiplica, Anca Aghinitei Zbranca Toporas, Simona Laura Ianosi, Ion, Florea, Claus, Zachariae, Lars, Iversen, Annalisa, Patrizi, Romanelli, Marco, Christopher, Griffiths, John Berth Jones, John, Foerster, Savin, Ronald C., Nelson, Christopher G., Lyn Carol Chamberlain Guenther, Albrecht, Lorne E., Hong, Chih ho H., Arnon, Katz, Mani, Raman, Adam, David N., Aamir, Butt, Stephen Peter Shumack, Kurt Aaron Josef Gebauer, Lynda Jane Spelman, Shireen Kaur Sidhu, Michael George Freeman, Peter Anthony Foley, Lajos, Kemeny, Eva, Remenyik, Zsuzsanna, Karolyi, Marc, Bourcier, Wayne Douglas Carey, Victoria, Taraska, Derek, Haaland, Aditya Kumar Gupta, Catherine, Maari, Darryl Paul Toth, Michael, Sebastian, Sandra, Philipp, Roland, Kaufmann, Diamant, Thaci, Thomas Andreas Werfel, Leila, Parise, Ingo, Haase, Petra Staubach Renz, Shinichi, Imafuku, Juichiro, Nakayama, Tadashi, Terui, Hideki, Nakajima, Shigetoshi, Sano, Uncover, 2 Study Group, Uncover, 3 Study Group

Publikováno v: New England Journal of Medicine. 375:345-356

BACKGROUND Two phase 3 trials (UNCOVER-2 and UNCOVER-3) showed that at 12 weeks of treatment, ixekizumab, a monoclonal antibody against interleukin-17A, was superior to placebo and etanercept in the treatment of moderate-to-severe psoriasis. We repor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fb30bf3a03c1849628a03f8c5fc3e43
https://doi.org/10.1056/nejmoa1512711